NCT00151827View on ClinicalTrials.gov

Olmesartan Medoxomil in Hypertension and Renal Impairment

PHASE3CompletedINTERVENTIONAL
Enrollment

393

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

July 31, 2005

Study Completion Date

July 31, 2005

Conditions
Essential HypertensionRenal Impairment
Interventions
DRUG

Olmesartan medoxomil

Olmesartan oral tablets 20 or 40 mg + losartan placebo. Medications are taken once daily before breakfast with water.

DRUG

Losartan

Medications are taken once daily before breakfast with water.

DRUG

Furosemide oral tablets

If its use is necessary, the dose of furosemide allowed is 20 to 120 mg per day at the discretion of the investigator

Trial Locations (1)

Unknown

Darmstadt

All Listed Sponsors
lead

Sankyo Pharma Gmbh

INDUSTRY

NCT00151827 - Olmesartan Medoxomil in Hypertension and Renal Impairment | Biotech Hunter | Biotech Hunter